âAfter more than a decade of joint respiratory research and development, the approval is a very important milestone for Theravance and GSK.â. Following this approval by the FDA, it is anticipated that BREO ELLIPTA will be available in the US during the third quarter of 2013. Under the terms of the 2002 LABA collaboration agreement, Theravance is obligated to make a milestone payment of $30 million (USD) to GSK following FDA approval of BREO ELLIPTA.
More on The Christian Science Monitor. The Christian Science Monitor is an independent international news organization with the stated goal of understanding the worldâs problems in order to move toward solutions. Mary Baker Eddy, the founder of Church of Christ, Scientist, founded the Christian Science Monitor in 1908.
What Is A Heart Event Monitor? Event Monitors are medical devices which are used for heart disease testing and the diagnosis of chest pain. They record a person's heart electrical activity (ECG) and are usually prescribed by a doctor to diagnose a heart arrhythmia.